Cargando…
Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging. This study aims to determine meropenem plasma exposure in the CKD population and further investigate o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027930/ https://www.ncbi.nlm.nih.gov/pubmed/36959849 http://dx.doi.org/10.3389/fphar.2023.1126714 |
_version_ | 1784909822246780928 |
---|---|
author | Deng, Guoliang Yang, Fan Sun, Ning Liang, Danhong Cen, Anfen Zhang, Chen Ni, Suiqin |
author_facet | Deng, Guoliang Yang, Fan Sun, Ning Liang, Danhong Cen, Anfen Zhang, Chen Ni, Suiqin |
author_sort | Deng, Guoliang |
collection | PubMed |
description | Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging. This study aims to determine meropenem plasma exposure in the CKD population and further investigate optimal dosing regimens. Methods: A healthy adult PBPK model was established using the meropenem’s physicochemical parameters, pharmacokinetic parameters, and available clinical data, and it was scaled to the populations with CKD and dialysis. The differences between the predicted concentration, C(max), and AUC(last) predicted and observed model values were assessed by mean relative deviations (MRD) and geometric mean fold errors (GMFE) values and plotting the goodness of fit plot to evaluate the model’s performance. Finally, dose recommendations for CKD and hemodialysis populations were performed by Monte Carlo simulations. Results: The PBPK models of meropenem in healthy, CKD, and hemodialysis populations were successfully established. The MRD values of the predicted concentration and the GMFE values of C(max) and AUC(last) were within 0.5–2.0-fold of the observed data. The simulation results of the PBPK model showed the increase in meropenem exposure with declining kidney function in CKD populations. The dosing regimen of meropenem needs to be further adjusted according to the renal function of CKD patients. In patients receiving hemodialysis, since meropenem declined more rapidly during the on-dialysis session than the off-dialysis session, pharmacodynamic evaluations were performed for two periods separately, and respective optimal dosing regimens were determined. Conclusion: The established PBPK model successfully predicted meropenem pharmacokinetics in patients with CKD and hemodialysis and could further be used to optimize dosing recommendations, providing a reference for personalized clinical medication. |
format | Online Article Text |
id | pubmed-10027930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100279302023-03-22 Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals Deng, Guoliang Yang, Fan Sun, Ning Liang, Danhong Cen, Anfen Zhang, Chen Ni, Suiqin Front Pharmacol Pharmacology Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging. This study aims to determine meropenem plasma exposure in the CKD population and further investigate optimal dosing regimens. Methods: A healthy adult PBPK model was established using the meropenem’s physicochemical parameters, pharmacokinetic parameters, and available clinical data, and it was scaled to the populations with CKD and dialysis. The differences between the predicted concentration, C(max), and AUC(last) predicted and observed model values were assessed by mean relative deviations (MRD) and geometric mean fold errors (GMFE) values and plotting the goodness of fit plot to evaluate the model’s performance. Finally, dose recommendations for CKD and hemodialysis populations were performed by Monte Carlo simulations. Results: The PBPK models of meropenem in healthy, CKD, and hemodialysis populations were successfully established. The MRD values of the predicted concentration and the GMFE values of C(max) and AUC(last) were within 0.5–2.0-fold of the observed data. The simulation results of the PBPK model showed the increase in meropenem exposure with declining kidney function in CKD populations. The dosing regimen of meropenem needs to be further adjusted according to the renal function of CKD patients. In patients receiving hemodialysis, since meropenem declined more rapidly during the on-dialysis session than the off-dialysis session, pharmacodynamic evaluations were performed for two periods separately, and respective optimal dosing regimens were determined. Conclusion: The established PBPK model successfully predicted meropenem pharmacokinetics in patients with CKD and hemodialysis and could further be used to optimize dosing recommendations, providing a reference for personalized clinical medication. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10027930/ /pubmed/36959849 http://dx.doi.org/10.3389/fphar.2023.1126714 Text en Copyright © 2023 Deng, Yang, Sun, Liang, Cen, Zhang and Ni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Deng, Guoliang Yang, Fan Sun, Ning Liang, Danhong Cen, Anfen Zhang, Chen Ni, Suiqin Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals |
title | Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals |
title_full | Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals |
title_fullStr | Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals |
title_full_unstemmed | Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals |
title_short | Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals |
title_sort | physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in ckd and hemodialysis individuals |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027930/ https://www.ncbi.nlm.nih.gov/pubmed/36959849 http://dx.doi.org/10.3389/fphar.2023.1126714 |
work_keys_str_mv | AT dengguoliang physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals AT yangfan physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals AT sunning physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals AT liangdanhong physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals AT cenanfen physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals AT zhangchen physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals AT nisuiqin physiologicallybasedpharmacokineticpharmacodynamicevaluationofmeropeneminckdandhemodialysisindividuals |